International Biotechnol... Share Discussion Threads

[gilston] 06/12/2011 18:34

Tomorrow`s AGM should be interesting. The share buyback / cancellation process is very active.

[davebowler] 06/12/2011 15:58

Amazing really - this is at an all time high.

[gilston] 05/12/2011 16:45

Improving!

[davebowler] 25/10/2011 13:25

Edison;
International Biotechnology Trust - Improved fee structure PDF download Click for report

With the recent results announcement, International Biotechnology Trust (IBT) confirmed a reduction in the annual management fee by 20bps to 1.15% of NAV with the aim of reducing the overall TER to below 2.0%. The quoted portfolio performance fee is also being adjusted, to 10% of any outperformance above the NASDAQ (sterling adjusted) Biotechnology Index plus 0.5%. The maximum total performance fee payable in a year falls from 5% of NAV to 3%. For now, the unquoted portfolio continues to act as a break on overall performance. However, IBT has recently successful exited Cadent with a sale to Align Technologies, at 3.1x book value. While recent market conditions have arguably delayed further exits the manager, SV Life Sciences, believes many of the unquoted names are reaching maturity and will provide strong exits, which will give a significant uplift to the unquoted performance.

IBT aims to achieve long-term capital growth by investing in deve lopment stage biotechnology and other life sciences companies, both quoted and unquoted, that have high growth potential.

[davebowler] 17/10/2011 15:45

Date NAV Pence
Friday 14(th) October Excluding Income 174.08

[davebowler] 19/9/2011 09:55

Thursday 15 September NAV Excluding Income 172.77

[davebowler] 09/9/2011 12:26

NAV Thursday 08 September 170.52

[davebowler] 05/9/2011 13:56

NAV Friday 02 September Excluding Income 164.25

[davebowler] 19/5/2011 13:23

18 May 2011

International Biotechnology Trust plc

The Board of International Biotechnology Trust plc announces that the unaudited net asset value per share


Date NAV Pence
Tuesday 17 May Excluding Income 183.34

[davebowler] 26/4/2011 13:58

Wednesday 20 April NAV 179.01

[davebowler] 14/4/2011 10:10

Tuesday 12 April NAV 177.3

[davebowler] 11/4/2011 13:51

Friday 08 April NAV Excluding Income 176.90

[davebowler] 31/12/2010 16:21

Thursday 30 December NAV Excluding Income 181.09

[davebowler] 27/12/2010 10:42

https://www.winsresearch.co.uk/secure/files.php?file_id=334&file_type=wins-update

[davebowler] 24/12/2010 11:25

23/12 NAV 180.35

[davebowler] 21/12/2010 09:33

now at 18% discount to NAV;

[davebowler] 20/12/2010 15:47

Intl. Biotechnology Trust PLC

17 December 2010

INTERNATIONAL BIOTECHNOLOGY TRUST PLC

Portfolio Update as at 30 November 2010


Total net assets GBP99.4m
NAV per share 166.3p
Share price 137.0p
Total value of unquoted investments GBP23.3m
Total number of portfolio companies 60
Cash 1% NAV
Cash committed and reserved to 9% NAV
unquoted investments
Portfolio companies with < 1 year 10% NAV
of cash


Top Ten Holdings


Company Name % NAV
Celgene 5.80
Micromet 5.77
Amgen 5.30
Shire Ltd 5.16
Gilead Sciences 4.83
Alexion Pharmaceuticals 3.54
Teva 3.43
Insulet 3.39
Genzyme 3.27
Cadent 3.25
-----------
Total 43.74


Geographical Allocation %
United States 74
Europe 23
Australia 2
Cash 1
-----------
Total 100


Quoted/Unquoted allocation %
Quoted 76
Unquoted 23
Cash 1
-----------
Total 100

[davebowler] 03/11/2010 09:29

Edison note;

During the 12 months to 31 August 2010 International Biotechnology Trust (IBT) underperformed the NASDAQ Biotechnology Index (NASBIOT) – large cap biased by 4.2% in terms of NAV total return, but outperformed Russell 2000 Biotechnology Growth Index (R2BIOG) – small cap biased by 11.5%. In terms of share price total return, IBT outperformed the NASBIOT by 4.2% and the R2BIOG by 19.9%. The superior share price performance, over the NAV, reflects a narrowing of the discount during the period. The manager considers that biotech has suffered from substantial negative sentiment during the last year and investors' appetite for risk is much diminished. The manager expects that, as this returns, valuations will move up from their current historic lows offering significant upside potential.

International Biotechnology Trust aims to achieve long-term capital growth by investing in development stage biotechnology companies that are either quoted or unquoted with the potential for high growth.

[yespmedc] 03/11/2010 08:32

New note -